NOX5 as a therapeutic target in cerebral ischemic injury

Area of Science:

• Biomedical research
• Neuroscience
• Cardiovascular research

Background:

• NADPH oxidase (NOX) enzymes are implicated in oxidative stress and inflammation.
• Cerebral ischemia, or stroke, leads to significant neurological damage and is a leading cause of death and disability.
• The specific role of NOX5 in the context of cerebral infarction remains largely undefined.

Purpose of the Study:

• To elucidate the role of the NADPH oxidase catalytic subunit NOX5 in the pathogenesis of cerebral infarction.
• To investigate the therapeutic potential of inhibiting NOX5 in a preclinical stroke model.

Main Methods:

• Utilized a mouse model engineered to express human NOX5 specifically in the endothelium.
• Induced cerebral ischemia to mimic stroke conditions.
• Administered a novel pharmacological inhibitor of NOX5, ML090, at the time of reoxygenation.
• Assessed outcomes including cerebral edema, infarct size, neurological function, and blood-brain barrier (BBB) integrity.

Main Results:

• NOX5 was found to be activated following cerebral ischemia in the endothelium.
• Activation of NOX5 contributed to BBB breakdown, leading to cerebral edema, infarction, and worsened neurological deficits.
• Early administration of the NOX5 inhibitor ML090 effectively maintained BBB integrity and mitigated stroke-induced damage.
• ML090 treatment resulted in improved neurological function in the experimental model.

Conclusions:

• The NADPH oxidase catalytic subunit NOX5 plays a detrimental role in cerebral infarction by compromising blood-brain barrier integrity.
• Pharmacological inhibition of NOX5, particularly with early intervention around reoxygenation, represents a promising therapeutic strategy for stroke.
• Targeting NOX5 warrants further investigation for potential clinical application in stroke management, especially in conjunction with thrombolysis.